http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 12:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Press+Releases/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html <p align="justify">MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company’s proprietary gel-based delivery platform.</p> <p align="justify">Gelteq tested a variety of products, including a range deliberately formulated with natural bitter compounds that canines would ordinarily reject.</p> <p align="justify">The results demonstrated strong canine acceptance across the flavour profiles and confirmed http://www.streetinsider.com/Globe+Newswire/Gelteq+Successfully+Completes+Veterinary+Palatability+Trials+with+Kemin%2C+Further+Validating+Gelteq%C2%AE+Technology+for+Animal+Health+Applications/26639675.html Fri, 12 Jun 2026 12:30:00 -0400 A.23072780 GELS O.05002822 O.32615741 http://www.streetinsider.com/Corporate+News/Gelteq+opens+China+center+to+boost+drug+development+operations/26603448.html <p>Gelteq Limited (NASDAQ: GELS) announced the establishment of a Center of Excellence in Guangdong Province, China, according to a company statement. The Melbourne-based biotechnology company said the facility will serve as a regional hub for product development and commercial activities.</p><p>The center is designed to support accelerated product development timelines, expanded formulation and testing capabilities, and increased capacity for multiple development programs, the company stated. Gelteq develops drug delivery technology in an ingestible gel form aimed at improving how active ingredients are absorbed by the body.</p><p>"This Center of Excellence represents a significant milestone in expanding Gelteq's global development and commercial capabilities," http://www.streetinsider.com/Corporate+News/Gelteq+opens+China+center+to+boost+drug+development+operations/26603448.html Thu, 04 Jun 2026 09:08:53 -0400 GELS http://www.streetinsider.com/Press+Releases/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html <p>MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems.</p> <p><strong>Enhancing Development Capabilities Through Regional Hub</strong></p> <p>The establishment of Gelteq’s Guangdong Province-based Center of Excellence will strengthen the Company’s globally integrated development platform by leveraging regional infrastructure, technical expertise, and established innovation networks.</p> <p>The hub is expected to support:</p> http://www.streetinsider.com/Press+Releases/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html Thu, 04 Jun 2026 09:08:00 -0400 GELS O.32615741 http://www.streetinsider.com/Press+Releases/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html <p>MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems.</p> <p><strong>Enhancing Development Capabilities Through Regional Hub</strong></p> <p>The establishment of Gelteq’s Guangdong Province-based Center of Excellence will strengthen the Company’s globally integrated development platform by leveraging regional infrastructure, technical expertise, and established innovation networks.</p> <p>The hub is expected to support:</p> http://www.streetinsider.com/Press+Releases/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html Thu, 04 Jun 2026 09:08:00 -0400 GELS O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html <p>MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems.</p> <p><strong>Enhancing Development Capabilities Through Regional Hub</strong></p> <p>The establishment of Gelteq’s Guangdong Province-based Center of Excellence will strengthen the Company’s globally integrated development platform by leveraging regional infrastructure, technical expertise, and established innovation networks.</p> <p>The hub is expected to support:</p> http://www.streetinsider.com/Globe+Newswire/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html Thu, 04 Jun 2026 09:08:00 -0400 GELS O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html <p>MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world’s fastest-growing pharmaceutical and biotechnology ecosystems.</p> <p><strong>Enhancing Development Capabilities Through Regional Hub</strong></p> <p>The establishment of Gelteq’s Guangdong Province-based Center of Excellence will strengthen the Company’s globally integrated development platform by leveraging regional infrastructure, technical expertise, and established innovation networks.</p> <p>The hub is expected to support:</p> http://www.streetinsider.com/Globe+Newswire/Gelteq+Establishes+Center+of+Excellence+in+China+to+Accelerate+Product+Development+and+Commercial+Expansion/26603446.html Thu, 04 Jun 2026 09:08:00 -0400 GELS O.32615741 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+Jun+02/26591529.html si-local-file:///var/storage/secattach/20260602/26591529.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+Jun+02/26591529.html Tue, 02 Jun 2026 16:05:00 -0400 GELS O.32615741 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+Jun+02/26591529.html si-local-file:///var/storage/secattach/20260602/26591529.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+Jun+02/26591529.html Tue, 02 Jun 2026 16:05:00 -0400 GELS O.32615741 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+May+26/26549864.html si-local-file:///var/storage/secattach/20260526/26549864.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+May+26/26549864.html Tue, 26 May 2026 16:07:00 -0400 GELS O.32615741 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+May+26/26549864.html si-local-file:///var/storage/secattach/20260526/26549864.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Gelteq+Ltd++++++++++++++++For%3A+May+26/26549864.html Tue, 26 May 2026 16:07:00 -0400 GELS O.32615741 http://www.streetinsider.com/Corporate+News/Gelteq+begins+veterinary+clinical+trial+for+antiparasitic+drug+candidate/26525165.html <p>Gelteq Limited (NASDAQ: GELS) announced it has started its first clinical trial for an antiparasitic drug candidate using its proprietary delivery technology, according to a company statement.</p><p>The Melbourne-based biotechnology company said the trial aims to support a planned FDA regulatory submission for animal use, with a potential application targeted for later in 2026.</p><p>"This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market," said Nathan Givoni, CEO of Gelteq. "Building on our prior regulatory progress with the FDA, we are now advancing a key drug candidate powered by Gelteq® technology into the clinical stage http://www.streetinsider.com/Corporate+News/Gelteq+begins+veterinary+clinical+trial+for+antiparasitic+drug+candidate/26525165.html Wed, 20 May 2026 08:01:55 -0400 GELS http://www.streetinsider.com/Press+Releases/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html <p>MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.</p> <p>The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.</p> <p>“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with http://www.streetinsider.com/Press+Releases/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html Wed, 20 May 2026 08:00:00 -0400 GELS O.32615741 http://www.streetinsider.com/Press+Releases/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html <p>MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.</p> <p>The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.</p> <p>“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with http://www.streetinsider.com/Press+Releases/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html Wed, 20 May 2026 08:00:00 -0400 GELS O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html <p>MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.</p> <p>The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.</p> <p>“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with http://www.streetinsider.com/Globe+Newswire/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html Wed, 20 May 2026 08:00:00 -0400 GELS O.32615741 http://www.streetinsider.com/Globe+Newswire/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html <p>MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.</p> <p>The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.</p> <p>“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with http://www.streetinsider.com/Globe+Newswire/Gelteq+Commences+Veterinary+Medicine+Clinical+Trial+to+Support+an+FDA+Regulatory+Pathway/26525123.html Wed, 20 May 2026 08:00:00 -0400 GELS O.32615741 http://www.streetinsider.com/Press+Releases/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html <p><i><strong>2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market</strong></i></p> <p><strong id="dateline">LAS VEGAS, NV / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2026 / </strong>Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported record results for the first quarter ended March 31, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.</p><p><strong>Q1 2026 Financial Highlights</strong></p><ul style="list-style-type:disc;"><li><p>Net revenue increased 73% to record $1.6 million, with the strong growth largely due to the merger with Gummy USA^™ http://www.streetinsider.com/Press+Releases/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html Thu, 14 May 2026 08:35:00 -0400 GELS HYEX http://www.streetinsider.com/Press+Releases/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html <p><i><strong>2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market</strong></i></p> <p><strong id="dateline">LAS VEGAS, NV / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2026 / </strong>Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported record results for the first quarter ended March 31, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.</p><p><strong>Q1 2026 Financial Highlights</strong></p><ul style="list-style-type:disc;"><li><p>Net revenue increased 73% to record $1.6 million, with the strong growth largely due to the merger with Gummy USA^™ http://www.streetinsider.com/Press+Releases/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html Thu, 14 May 2026 08:35:00 -0400 GELS HYEX http://www.streetinsider.com/ACCESS+Newswire/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html <p><i><strong>2026 Outlook Strengthened by New Major Global Partnership with Sommer Ray's Imaraïs Beauty and Entrance into $730 Billion Health & Beauty Market</strong></i></p> <p><strong id="dateline">LAS VEGAS, NV / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 14, 2026 / </strong>Healthy Extracts Inc. (OTCQB:HYEX), a leader in nutraceutical innovations and precision dose gummy manufacturing, reported record results for the first quarter ended March 31, 2026. Financial comparisons are to the same year-ago period unless otherwise noted.</p><p><strong>Q1 2026 Financial Highlights</strong></p><ul style="list-style-type:disc;"><li><p>Net revenue increased 73% to record $1.6 million, with the strong growth largely due to the merger with Gummy USA^™ http://www.streetinsider.com/ACCESS+Newswire/Healthy+Extracts+Q1+2026+Net+Revenue+Up+73%25+to+Record+%241.6+Million%2C+Driving+Positive+EBITDA/26490768.html Thu, 14 May 2026 08:35:00 -0400 GELS HYEX